Comparative Pharmacology
Head-to-head clinical analysis: AVC versus SULFACEL 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVC versus SULFACEL 15.
AVC vs SULFACEL-15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVC (sulfanilamide) is a sulfonamide antibiotic that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid (PABA), thereby blocking folic acid production and bacterial growth.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate, thereby inhibiting folate synthesis and bacterial growth.
1 applicatorful (approximately 5 g of 0.1% cream) intravaginally once daily at bedtime for 7 days.
Adults: 15 mg/kg orally every 6 hours for 10 days; maximum single dose 1 g.
None Documented
None Documented
3-5 hours; prolonged in renal impairment (up to 12 hours).
Expected ~6-9 hours based on related sulfacetamide; however, no specific data for SULFACEL-15. Clinical context: prolonged in renal impairment.
Renal: 30-50% unchanged; biliary/fecal: 10-20% as metabolites.
Renal: ~85-90% unchanged; Biliary/Fecal: ~5-10% (metabolites and unchanged drug); ~5% eliminated via feces following biliary secretion.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)